This MedLibrary.org supplementary page on Fungal pneumonia is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. (July 2008) |
| Pneumonia | |
 |
|
| Infectious pneumonias | |
|---|---|
| Pneumonias caused by infectious or noninfectious agents | |
| Noninfectious pneumonia | |
Fungal pneumonia is an infection of the lungs by fungi. It can be caused by either endemic or opportunistic fungi or a combination of both. Case mortality in fungal pneumonias can be as high as 90% in immunocompromised patients[1] [2] , though immunocompetent patients generally respond well to anti-fungal therapy.
Contents |
Pathogens
Specific instances of fungal infections that can manifest with pulmonary involvement include:
- histoplasmosis, which has primary pulmonary lesions and hematogenous dissemination
- coccidioidomycosis, which begins with an often self-limited respiratory infection (also called "Valley fever" or "San Joaquin fever")
- pulmonary blastomycosis
- pneumocystis pneumonia, which typically occurs in immunocompromised people, especially AIDS
- sporotrichosis - primarily a lymphocutaneous disease, but can involve the lungs as well
- cryptococcosis - contracted through inhalation of soil contaminated with the yeast, it can manifest as a pulmonary infection and as a disseminated one
- aspergillosis, resulting in invasive pulmonary aspergillosis
- rarely, candidiasis has pulmonary manifestations in immunocompromised patients.
Pathophysiology
Fungi typically enter the lung with inhalation of their spores, though they can reach the lung through the bloodstream if other parts of the body are infected. Also, fungal pneumonia can be caused by reactivation of a latent infection. Once inside the alveoli, fungi travel into the spaces between the cells and also between adjacent alveoli through connecting pores. This invasion triggers the immune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophils) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system. This results in the fever, chills, and fatigue common in bacterial and fungal pneumonia. The neutrophils and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.
Diagnosis
Fungal pneumonia can be diagnosed in a number of ways. The simplest and cheapest method is to culture the fungus from a patient's respiratory fluids; such tests are insensitive and are also slow, time being a critical factor in preventing mortality. Studies have shown that slow diagniosis of fungal pneumonia is linked to high mortality(e.g.[3]). Microscopy is also a slow and impresice method. Supplementing classical methods is the detection of antigens, notably, galactomannan and ß-1-3 D glucan in Aspergillus. [4] Such methods are faster, but are currently confined to Aspergillus, and can be les sensitive and specific than classical methods. [5]
A molecular test based on real-time PCR is also available, from Myconostica. this test relies on DNA detection, and as such is the fastest, most sensitive and most specific test available for fungal pneumonia [6] This method requires more expertise than methods such as culturing, and is more expensive.
Treatment
Fungal pneumonia can be treated with antifungal drugs and sometimes by surgical debridement.
References
- ^ , Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E. Invasive aspergillosis in the intensive care unit. Clin Infect Dis. 2007 Jul 15;45(2):205-16.
- ^ , Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J. 2007 Oct;30(4):782-800.
- ^ , Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005;49:3640-5.
- ^ , Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. Lancet Infectious Diseases 2005:9:609-22.
- ^ Webinar on fungal diagnostics, D Denning, September 2008.
- ^ , Philippe Hauser, Lagrou K, Cui X, PerlinD S, Park S, Harrison E, Meerssman W, Hughes M J, Bowyer P, Denning DW, Bille J, Lass-Flor C, Maertens J. Clinical performance of FXG™ : RESP (Asp +) assay for Aspergillus spp. and Pneumocystis jirovecii on respiratory specimens. Unpublished Data.
External links
See also
 |
This disease article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 9 October 2008, at 09:26.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Fungal pneumonia".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.